Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-23 20:59 | 2026-09-23 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Director | BUY | $100.00 | 5,000 | $500,000 | 434,360 |
| 2026-09-23 20:07 | 2026-09-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | SELL | $165.49 | 1,687 | $279,183 | 618,902 |
| 2026-09-23 20:07 | 2026-09-21 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $165.49 | 294 | $48,654 | 116,720 |
| 2026-09-23 20:08 | 2026-09-21 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $165.49 | 348 | $57,591 | 73,303 |
| 2026-09-22 22:43 | 2026-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Officer | OPT+S | $13.65 | 1,635 | $22,318 | 8,617 |
| 2026-09-22 22:00 | 2026-09-18 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer | SELL | $196.94 | 1,764 | $347,402 | 40,352 |
| 2026-09-22 21:04 | 2026-09-21 | BNTX | BioNTech SE | Sahin Ugur | Officer, 10% owner | SELL | $99.50 | 79,000 | $7,860,761 | 410,209 |
| 2026-09-22 20:07 | 2026-09-21 | RGEN | REPLIGEN CORP | Loeillot Olivier | Director, Officer | OPT+S | $180.00 | 5,426 | $976,680 | 48,369 |
| 2026-09-21 22:40 | 2026-09-17 | CRSP | CRISPR Therapeutics AG | Behbahani Ali | Director | OPT+S | $57.09 | 13,679 | $780,935 | 16,637 |
| 2026-09-21 20:05 | 2026-09-17 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | OPT+S | $157.99 | 356,546 | $56,330,738 | 620,589 |
| 2026-09-19 00:17 | 2026-09-16 | ADPT | Adaptive Biotechnologies Corp | LO FRANCIS | Officer | OPT+S | $28.06 | 115,406 | $3,238,004 | 220,867 |
| 2026-09-18 22:00 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | Officer | SELL | $199.24 | 4,053 | $807,513 | 119,216 |
| 2026-09-18 22:01 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | Officer | SELL | $199.24 | 3,366 | $670,631 | 52,541 |
| 2026-09-18 22:02 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | GOLDSMITH MARK A | Director, Officer | SELL | $199.24 | 13,988 | $2,786,938 | 253,342 |
| 2026-09-18 22:03 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | Officer | SELL | $199.24 | 4,967 | $989,613 | 149,680 |
| 2026-09-18 22:04 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | Officer | SELL | $199.24 | 5,569 | $1,109,554 | 286,307 |
| 2026-09-18 22:05 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer | SELL | $199.24 | 1,774 | $353,449 | 42,116 |
| 2026-09-18 22:06 | 2026-09-16 | RVMD | Revolution Medicines, Inc. | Sandler Alan B. | Officer | SELL | $199.24 | 341 | $67,941 | 52,868 |
| 2026-09-18 20:41 | 2026-09-17 | BNTX | BioNTech SE | Sahin Ugur | Officer, 10% owner | SELL | $97.49 | 64,000 | $6,239,072 | 489,209 |
| 2026-09-18 12:30 | 2026-09-17 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.21 | 24,000 | $4,992 | 126,822 |
| 2026-09-17 20:22 | 2026-09-15 | TARS | Tarsus Pharmaceuticals, Inc. | LINK WILLIAM J PHD | Director | OPT+S | $78.38 | 12,500 | $979,745 | 94,487 |
| 2026-09-17 22:50 | 2026-09-15 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer | SELL | $27.00 | 1,195 | $32,265 | 395,794 |
| 2026-09-17 21:46 | 2026-09-16 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Director | BUY | $100.00 | 5,000 | $500,000 | 429,360 |
| 2026-09-17 21:19 | 2026-09-16 | HALO | HALOZYME THERAPEUTICS, INC. | Posard Matthew L. | Director | SELL | $107.74 | 18,996 | $2,046,582 | 58,839 |
| 2026-09-17 20:30 | 2026-09-15 | CGON | CG Oncology, Inc. | POST LEONARD E | Director | OPT+S | $72.98 | 1,000 | $72,980 | 0 |
| 2026-09-17 16:01 | 2026-09-16 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.21 | 11,000 | $2,310 | 102,822 |
| 2026-09-16 20:27 | 2026-09-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | SELL | $144.22 | 3,000 | $432,646 | 116,684 |
| 2026-09-16 21:57 | 2026-09-14 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $8.57 | 123,918 | $1,062,510 | 3,172,141 |
| 2026-09-16 21:13 | 2026-09-14 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer | SELL | $13.90 | 58,333 | $811,004 | 767,486 |
| 2026-09-16 20:46 | 2026-09-15 | BNTX | BioNTech SE | Sahin Ugur | Officer, 10% owner | SELL | $96.37 | 49,000 | $4,721,978 | 553,209 |
| 2026-09-16 20:48 | 2026-09-14 | MRNA | Moderna, Inc. | Hoge Stephen | Officer | OPT+S | $145.10 | 80,575 | $11,691,416 | 1,562,029 |
| 2026-09-16 20:30 | 2026-09-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer | SELL | $145.29 | 3,000 | $435,870 | 164,096 |
| 2026-09-16 20:05 | 2026-09-15 | FENC | FENNEC PHARMACEUTICALS INC. | Brughera Marco Maria | Director | OPT+S | $10.29 | 15,545 | $159,958 | 0 |
| 2026-09-16 20:06 | 2026-09-15 | DNA | Ginkgo Bioworks Holdings, Inc. | HENRY CHRISTIAN O | Director | SELL | $7.08 | 5,000 | $35,405 | 19,310 |
| 2026-09-16 13:15 | 2026-09-15 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.22 | 22,000 | $4,862 | 91,822 |
| 2026-09-15 20:05 | 2026-09-14 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Director | BUY | $0.56 | 10,000 | $5,620 | 50,000 |
| 2026-09-15 22:25 | 2026-09-14 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $1.93 | 1,658 | $3,200 | 502,907 |
| 2026-09-15 22:25 | 2026-09-14 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | Officer | SELL | $1.93 | 2,587 | $4,993 | 509,198 |
| 2026-09-15 22:00 | 2026-09-11 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | Officer | OPT+S | $202.36 | 92,531 | $18,724,767 | 291,876 |
| 2026-09-15 21:52 | 2026-09-11 | INBX | Inhibrx Biosciences, Inc. | MANHARD KIMBERLY | Director | SELL | $109.03 | 1,500 | $163,542 | 7,500 |
| 2026-09-15 21:02 | 2026-09-14 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | Officer | SELL | $157.20 | 2,311 | $363,285 | 42,808 |
| 2026-09-15 21:03 | 2026-09-14 | NBIX | NEUROCRINE BIOSCIENCES INC | Boyer David W. | Officer | SELL | $157.45 | 826 | $130,051 | 8,722 |
| 2026-09-15 20:30 | 2026-09-14 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.22 | 5,900 | $1,292 | 69,822 |
| 2026-09-14 22:03 | 2026-09-10 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer | OPT+S | $204.16 | 15,448 | $3,153,807 | 43,890 |
| 2026-09-14 20:50 | 2026-09-11 | BNTX | BioNTech SE | Sahin Ugur | Officer, 10% owner | SELL | $98.13 | 86,000 | $8,439,335 | 602,209 |
| 2026-09-14 20:25 | 2026-09-10 | MRNA | Moderna, Inc. | Mock James M | Officer | OPT+S | $134.49 | 34,836 | $4,685,094 | 59,375 |
| 2026-09-12 01:13 | 2026-09-09 | OCGN | Ocugen, Inc. | Musunuri Shankar | Director, Officer | SELL | $1.12 | 525,991 | $589,110 | 1,088,035 |
| 2026-09-12 00:35 | 2026-09-09 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $107.28 | 60,000 | $6,436,710 | 767,780 |
| 2026-09-11 23:51 | 2026-09-09 | MGX | Metagenomi Therapeutics, Inc. | Reid Laurence | Director | BUY | $1.17 | 20,000 | $23,402 | 20,000 |
| 2026-09-11 22:12 | 2026-09-10 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | Director, Officer | OPT+S | $11.28 | 280,245 | $3,160,771 | 113,321 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.